This product has a broad-spectrum antibacterial effect, especially against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against most bacteria of the Enterobacteriaceae family (including Citrobacter, cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc.). It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. It has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It also has good effects on Chlamydia trachomatis, Mycoplasma, Legionella, and antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. It has poor antibacterial activity against anaerobic bacteria. Ciprofloxacin is a bactericide that acts on the A subunit of bacterial DNA gyrase, inhibiting DNA synthesis and replication, leading to bacterial death.

It is a clofibrate lipid regulator that can inhibit the synthesis of cholesterol and triglycerides and increase the excretion of sterols. In addition, it can also reduce plasma fibrinogen content and platelet viscosity and reduce thrombus formation.

It can bind to hydroxyapatite in bones and inhibit bone resorption. At the cellular level, this product inhibits osteoclasts. Histomorphometric measurements of rats, dogs, and piglets revealed that this product can reduce bone turnover and resorption at the bone remodeling site. Animal experiments suggest that this product can inhibit osteoclasts and bone resorption in osteoporosis model rats and miniature pigs. After oral administration of this product to rats and piglets, bone mass and bone biomechanical strength increased in a dose-dependent manner, and the increase in bone density was associated with the above changes.

Quinolone antibiotics, the main mechanism of action is to inhibit bacterial DNA gyrase activity and inhibit bacterial DNA replication. They have good antibacterial effects on most Enterobacteriaceae, some Staphylococci, Streptococcus pneumoniae, Haemophilus influenzae, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Chlamydia, etc., with a broad antibacterial spectrum and strong antibacterial effects.